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ABSTRACT
Objective: Agomelatine is a new mechanism of antidepressants, which is approved by Taiwan Food and Drug Administration and available in Taiwan. 
Agomelatine behaves both as a potent agonist at melatonin MT1 and MT2 receptors and as a neutral antagonist at 5-HT2C receptors. The structures 
of agomelatine are similar to melatonin with not only the effects to maintain depression symptoms but also can help patients who have insomnia.
Methods: This is a retrospective study. In a mental hospital in Taoyuan, we analyzed the prescriptions of the outpatients who were prescribed 
agomelatine to realize the effects of agomelatine and whether the prescriptions were prescribed appropriately.
Results: Catastrophic illnesses were found to be associated with significantly used multiple hypnotics (χ2 =22.02, p<0.001). When patients’ age 
increased by 1 year, multiple hypnotics used increased by 1.013 times (Exp(B)=1.013, p<0.01). Catastrophic illnesses were found to be associated 
with significantly used augmentation with other antidepressants (χ2=54.07, p<0.001).
Conclusions: Doctors should be evaluating the benefits and risks when they prescribe a medicine to patients, and they should be written in medical 
record. This study is the hope to provide relevant units as a reference for formulating health policies.
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INTRODUCTION
Major depressive disorder (MDD) is one of the most common, 
burdensome, and costly psychiatric disorders worldwide in adults [1]. 
Depression and anxiety disorders are commonly comorbid with each 
other, with estimates of current and lifetime comorbidity often among 
the highest of any disorders [2]. Although sleep disturbance is a criterion 
for depression, insomnia is also increasingly being conceptualized as a 
mechanism in depression etiology [2].
In February 2009, the European Medicine Agency approved agomelatine, 
a sleep modulating antidepressant, for the treatment of MDD. In 
adults, it is awaiting approval from the Federal Drug Administration 
in the USA [3]. Agomelatine is the first approved antidepressant that 
mediates its activity through the melatoninergic pathway rather than 
the monoaminergic system [3]. It was approved by Taiwan Food and 
Drug Administration and available in Taiwan from July 2011.
Agomelatine is an agonist at both melatoninergic MT1 and MT2 
receptors; it also has an affinity for 5-HT2C receptor, but it is unlikely 
that antidepressants effects are mediated through these receptors [4,5]. 
Agomelatine is a highly accepted antidepressant drug, but there is no 
definite conclusion about the exact effect of the system [1,6].
The indication for agomelatine is MDD in adults. The initial dose is 
recommended to be used at bedtime of 25 mg/day. If there is no effect 
after 2 weeks of treatment, increasing to 50 mg before bedtime is 
considered [7].
In the Sidney study, [6] in total, 633 patients (422 on agomelatine; 
211 on placebo) were included in the analysis. At endpoint, there was 
a significant difference in favor of agomelatine versus placebo of 3.47 
(0.62) (95% confidence interval: [2.26; 4.67]; p<0.001) on the SDS total 
score. This study confirms the efficacy of agomelatine in improving 
social functioning in MDD patients.
When using antidepressants, liver function injury should be 
monitored. A retrospective study by Freiesleben [7] showed that 
the incidence of liver toxicity caused by agomelatine compared to 
placebo was 4.6% and 2.1%; the incidence of hepatotoxicity with 
some other antidepressant drugs is escitalopram 1.4%, paroxetine 
0.6%, fluoxetine 0.4%, and sertraline 0%. A retrospective study by 
Voican et al. [8] has showed that hepatotoxicity was caused by six 
antidepressant drugs, although only 0.5–5% of patients will have mild 
hepatotoxicity, liver damage is usually unpredictable and most of them 
occur in elderly people with multiple medications. Therefore, before 
increasing the dosage and using this medicine, patient’s benefits and 
risks should be evaluated.
Agomelatine has been used in MDD since December 2015. It is a new 
mechanism of antidepressants in Taiwan. Through its mechanism, 
agomelatine might be a better choice for people who have both 
insomnia and depressive disorder.
METHODS
Study design
For this retrospective study of all outpatients who used agomelatine 
at one psychiatric hospital, Taoyuan Psychiatric Center (TYPC), we 
collected patient data from the hospital’s electronic medical information 
system from January to December in 2017. The system’s electronic 
medical information system was established in January 2000 and the 
diagnostic system we used is International Classification of Disease, 
Tenth, Clinical Modification (ICD-10-CM).
Study sample
This study was conducted at TYPC, a public, regional teaching 
hospital in North Taiwan. The facility has 282 acute beds, 380 
chronic beds, and 300 daycare beds, which treats an average of 1100 
patient visits per month and has 30 daycare beds and 30 acute care 
beds. The protocol for this study was approved by local institutional 
review board (IRB number: C20180730). Need for informed consent 
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was waived due to the retrospective nature of the study and ensured 
patient anonymity.
Research instrument, study variables, and data extraction
Data from the electronic medical information system of the study 
hospital are transformed into a relational database, referred to as the 
data “warehouse.”
We extracted study data from the warehouse and created our analytic 
data set using Social Sciences software version 22.0 for Windows 
(SPSS, Inc., Chicago, Illinois, USA). By reviewing the electronic medical 
information system, we extracted patients’ demographic data such as 
sex, age, insurance status, psychiatric diagnosis, and prescriptions for 
patients who were prescribed agomelatine.
The insurance status was divided into patients diagnosed with catastrophic 
illnesses and those without. The catastrophic illnesses in this study included 
bipolar disorder, current episode depressed, mild (ICD-10-CM:F31.31), 
MDD, recurrent severe without psychotic features (ICD-10-CM:F33.2), 
schizoaffective disorder, and depressive type (ICD-10-CM:F25.1).
Statistical analysis
Categorical variables were compared using Chi-square and Fisher’s 
exact tests, and continuous variables were compared using independent 
t-tests. Cochran-Armitage trend tests were performed to examine the 
time trends in the prescriptions of agomelatine and were estimated by 
multiple logistic regression analysis. We included all of the covariates in 
the multivariable logistic regression model, including age, gender, with 
or without catastrophic illnesses, and psychiatric diagnosis. All results 
were expressed as means and standard deviations.
All statistical analyses were performed using Statistical Package for the 
Social Sciences software version 22.0 for Windows (SPSS, Inc., Chicago, 
Illinois, USA). Group differences were considered significant if p <0.05 
was considered.
RESULTS
Table 1 shows the analysis of this study, 343 patients were included 
in this study. Females were 220 (64.14%); males were 123 (35.86%). 
Agomelatine was prescribed in 1760 visits. As shown in Table 2 
(χ2=1.38, p=0.23), a comparison between genders, there is no significant 
difference in gender used agomelatine.
The distribution of age is mainly 40–49 years old (30%), the average is 
49.97±15.83 years old; the range of age is from 10 to 92. The regression 
model p=0.630, we can presume that there is no difference in the way 
of taking agomelatine in different ages.
The diagnosis of those prescriptions of persistent depressive disorder 
(dysthymia) is part of a cluster of diagnoses called the depressive 
disorders (ICD-10-CM: F34.1) (14.2%) followed by other depressive 
episodes (ICD-10-CM: F32.8) (7.2%). In patients’ health insurance, 
catastrophic illnesses were 463 (26.1%), without catastrophic 
illnesses were 1297 (73.69%). As shown in Table 3 (χ2=0.17, p=0.67), a 
comparison between health insurance, there is no significant difference 
in the way of taking agomelatine in health insurance.
Evaluation of the appropriateness of prescriptions
From January to December 2017, doctors prescribed 1760 
prescriptions of agomelatine in outpatients. About 99.6% of frequency 
was accordance with the recommended use method of agomelatine; 7 
were taken at non-bedtime, 5 to be used as needed. All patients took 
agomelatine due to depressive disorder. The dosage is mainly from 
12.25 mg to 50 mg/day, which are all used in appropriate dosage. 25 mg 
of agomelatine is the most frequently used dosage (59.14%) in a day; in 
1760 prescriptions, 76.02% were combined with hypnotics.
In Table 4, hypnotics were prescribed 1753 times, and there were 
285 prescriptions containing two kinds of hypnotics. Among the 
Table 2: Comparison between genders
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Non-catastrophic illnesses 1297 73.69
Catastrophic illnesses 463 26.31
Dosage
12.5 mg 37 2.10
25 mg 1041 59.15
37.5 mg 7 0.40
50 mg 675 38.35
ICD-10-CM diagnosis
Dysthymic disorder 251 14.29
Other depressive episodes 128 7.29
Adjustment disorder with mixed anxiety and 
depressed mood
103 5.83
Major depressive disorder, recurrent, moderate 103 5.83
Major depressive disorder, recurrent, unspecified 92 5.25
Major depressive disorder, recurrent severe 
without psychotic features
87 4.96
Adjustment disorder with depressed mood 77 4.37
Other recurrent depressive disorders 67 3.79
Major depressive disorder, single episode, 
unspecified
67 3.79
Major depressive disorder, recurrent, severe with 
psychotic symptoms
67 3.79
Unspecified mood (affective) disorder 62 3.50
Others 657 32.32
prescriptions, short-acting zolpidem had the highest prescription rate 
(28.29%) followed by flurazepam (25.90%).
Regarding insurance status, prescriptions contained both agomelatine 
and hypnotics, catastrophic illnesses are 389 (22.10%), and without 
catastrophic illnesses are 949 (53.92%). As shown in Table 3 
(χ2 =22.02, p<0.001), catastrophic illnesses were found to be 
associated with significantly used multiple hypnotics. Age was also 
found to be associated with significantly used multiple hypnotics, and 
statistics indicates that when patients’ age increased by 1 year, multiple 
hypnotics used increased by 1.013 times (In Table 5, Exp(B)=1.013, 
p<0.01).
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DISCUSSION
To the best of our knowledge, this is the first study to focus on 
outpatients who used agomelatine to treat depressive disorder in 
psychiatric hospitals in Taiwan.
Agomelatine is an analog of melatonin, which means that it can treat 
not only depressive disorder but can also treat insomnia. Agomelatine 
increased slow-wave sleep and improved sleep quality and continuity, 
with no effect on REM sleep [9,10]. According to the analysis result, it 
showed patients who took agomelatine still needed hypnotics to solve 
their sleep problems. Among the hypnotics that had been chosen, 
zolpidem had the highest prescription rate (28.29%) followed by 
flurazepam (25.90%). There is no significant effect in insomnia with 
agomelatine but we should be concerned about patients’ tolerance in 
hypnotics before they use agomelatine.
Our univariate analysis showed that a higher proportion of females 
received agomelatine than males, though the difference was not 
significant.
In our data analysis result, although the safety patients under the 
age of 18 who use agomelatine was not established, it does not mean 
that agomelatine cannot be used under the age of 18. Doctors should 
evaluate the benefit when they are prescribing this medicine.
Some previous studies have found that antidepressant agents have the 
potential to produce idiopathic liver injury [8,11]. In our study result, 
there is only one case who had liver injury and used agomelatine. 
This study has some limitations because we included the data from 
patients in one psychiatric center. Thus, the diagnosis of some 
medical illnesses may not specifically be showed in patients’ medical 
records. The clinician must be careful to provide ongoing therapy 
of the underlying depressive disorder and be aware of possible 
drug discontinuation syndromes should potential hepatotoxicity be 
suspected [8]. Some patients have potential liver damage factors such 
as alcoholic abuse disorders, and patients’ liver function should be 
monitored.
CONCLUSIONS AND RECOMMENDATIONS
Doctors should be evaluating the benefits and risks when they prescribe 
a medicine to patients, and they should be written in medical record.
This study is the hope to provide relevant units as a reference for 
formulating health policies.
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